Allogeneic Stem Cell Transplant With Clofarabine, Ara-C and TBI for AML and ALL

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

January 31, 2016

Study Completion Date

March 31, 2016

Conditions
Acute Lymphoblastic LeukemiaAcute Myelogenous Leukemia
Interventions
DRUG

Clofarabine

Dose escalation of clofarabine on Days -9, -8, -7, -6, -5: 1 - 30 mg/m2; 2 - 40 mg/m2; 2 - 46 mg/m2; 3 - 52 mg/m2

DRUG

Clofarabine

Use dose of clofarabine established in Part A to further define event free, disease free and overall survival.

Trial Locations (1)

10595

New York Medical College, Vallhala

Sponsors
All Listed Sponsors
collaborator

Genzyme, a Sanofi Company

INDUSTRY

lead

New York Medical College

OTHER

NCT00529360 - Allogeneic Stem Cell Transplant With Clofarabine, Ara-C and TBI for AML and ALL | Biotech Hunter | Biotech Hunter